Phacilitate Leaders World

Speakers

Loading
Vincent Brichard

Vincent Brichard

Venture Partner, Life Science Partners
Vincent G. Brichard, MD, Ph.D., MBA, joined LSP in 2015 as a Venture Partner. He was formerly Senior Vice President and member of the Executive Team of GlaxoSmithKline (GSK) and headed the Business Unit for Immunotherapeutics. He is member of scientific advisory boards and supervisory boards of several European life sciences companies active in the fields of immuno-oncology, vaccines and diagnostics. He authored more than a 100 research manuscripts in leading international journals. He studied medicine at the Louvain University in Brussels and Institute Curie in Paris, received his Ph.D. in tumor immunology at the Ludwig Institute for Cancer Research in Brussels and had the position of a Professor of Oncology at Louvain University, Brussels. He also holds an executive MBA from Harvard Business School. Vincent lives in Belgium with his wife and 3 children. 
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK